跳至主要内容
临床试验/NCT03151278
NCT03151278已完成不适用

Multi-center, Randomized, Controlled Trial to Compare Feasibility, Safety and Efficacy of Zero-Fluoroscopic Navigation With Conventional Fluoroscopic Navigation for the Ablation of Right Atrial Arrhythmias

Tongji Hospital1 个研究点 分布在 1 个国家目标入组 212 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
212
试验地点
1
主要终点
Total success rates

研究概览

简要总结

This study is intended to compare the feasibility, safety and efficacy of a zero-fluoroscopic approach with conventional fluoroscopic approach as performing catheter ablation of right atrial arrhythmias.

详细描述

Catheter ablation is a well-established treatment to treat patients with a wide range of heart rhythm disturbances.

Fluoroscopy is the imaging modality routinely used for cardiac device implantation and electrophysiological procedures. Due to the rising concern regarding the harmful effects of radiation exposure to both the patients and operation staffs, novel three-dimensional mapping systems such as Ensite NavX have been developed and implemented in electrophysiological procedure for the navigation of catheters inside the heart chambers.

Ensite NavX is a promising system to guide catheters inside the cardiac chambers and vessels without the use of fluoroscopy.

This study is intended to compare the feasibility, safety and efficacy of a zero-fluoroscopic approach with conventional fluoroscopic approach as performing catheter ablation of right atrial arrhythmias.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Atrial Tachycardia
  • Atrial Premature Complexes

排除标准

  • Left Atrial Premature Complexes
  • Left Atrial Tachycardia

结局指标

主要结局

Total success rates

时间窗: 3 months

The patients have no related arrhythias or recurrence during follow up.

次要结局

  • Total procedure time(during procedure)
  • Recurrence rate(6 months)
  • Immediate success rate(24 hours)
  • Fluoroscopy time(during procedure)
  • Complications(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yan Wang

Professor

Tongji Hospital

研究点 (1)

Loading locations...

相似试验

已完成
3 期
A randomised, multi-centre trial to assess the feasibility of conducting a future phase III randomised trial in primary amyloidosis, comparing cyclophosphamide, thalidomide and dexamethasone with stem cell transplantation in patients with low risk of treatment related mortality and cyclophosphamide, thalidomide and dexamethasone with Mel-Dex in patients with high risk of treatment related mortalityAL amyloidosisNutritional, Metabolic, EndocrineMetabolic disorders
ISRCTN34235460niversity College London (UK)48
已完成
3 期
Multicentre, randomized controlled trial of the Frankfurt Early Intervention Program for tod-dlers and preschool children with Autism Spectrum Disorder – A-FFIPDSM-5: 299.0 Autism Spectrum DisorderF84.0F84.5Childhood autismAsperger syndrome
DRKS00016330Goethe Universität Frankfurt am Main134
招募中
Unknown
Effects of replacing the mask on facial bacterial growth and skin physiology in nursescontact dermatitis
JPRN-UMIN000053450Fujita Health University14
进行中(未招募)
不适用
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)
EUCTR2008-004007-64-DEGlaxoSmithKline Biologicals115
进行中(未招募)
1 期
An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma - MAGE3-AS15-MEL-001 (MET)First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanoma
EUCTR2008-004007-64-FIGlaxoSmithKline Biologicals125